The new vaccine is a tetravalent mosaic and is made up of four components. These components have been designed to help raise the body’s immune system to fight again the different strands of the virus. During the testing phase which was conducted on animals, it was found that two-thirds of the tests were successful, which means that while it isn’t a 100% cure or prevention, it does work to a certain degree.
These trials will begin with humans and will cover 3,800 men later this year. It will also cover a variety of regions including Europe, South America, and North America, which includes the US. Participants in the study are expected to receive six shots of the vaccine over four sessions, with the results from the trial expected in 2023.
Whether or not this could potentially result in a cure/prevention for the disease remains to be see, but it seems to be a good step in the right direction.